ロード中...

The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies

PURPOSE: A secondary epidermal growth factor receptor (EGFR) mutation, T790M, is the most common resistance mechanism in EGFR mutant adenocarcinomas that have progressed on erlotinib. Third generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A.
フォーマット: Artigo
言語:Inglês
出版事項: 2015
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4587765/
https://ncbi.nlm.nih.gov/pubmed/25964297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0560
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!